Search
On February 6, 2026, Johnson & Johnson's innovative drug Darzalex Faspro® (daratumumab injection for subcutaneous use) received approval from China's National Medical Products Administration to expand its indication. It can now be used in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma in adult patients eligible for autologous stem cell transplantation. This approval is based on the Phase III PERSEUS study, which showed that compared to the standard VRd regimen, the Darzalex Faspro® combination significantly reduced the risk of disease progression or death by 58%, and significantly improved the rates of minimal residual disease negativity and complete remission, providing patients with a new option to improve their prognosis.
-
C114 Communication Network -
Communication Home
